Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.

about

Hypertension in patients with cancer Review of systemic therapies for locally advanced and metastatic rectal cancer Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.Hypertension in malignancy-an underappreciated problem.

P2860

Q27003980-AF1AEF7B-447D-47FE-B1B2-E5456A6E4091 Q27021105-B65F15F4-71E6-4F99-BA12-1F1444D3EC94 Q39214055-8D792877-6E90-4FB8-B3A2-F46A28D06374 Q55071881-E620583E-8AF0-4082-9741-BFC00D4CDB32

P2860

Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.

Item

http://www.wikidata.org/entity/Q46062890

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@en

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@nl

type

Item

label

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@en

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@nl

prefLabel

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@en

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@nl

P1476

Shorter bevacizumab infusions ...... proteinuria and hypertension.

@en

P2093

E Marley

http://www.w3.org/2001/XMLSchema#string

J E Dowell

http://www.w3.org/2001/XMLSchema#string

J Liticker

http://www.w3.org/2001/XMLSchema#string

S M Gressett Ussery

http://www.w3.org/2001/XMLSchema#string

S R Shah

http://www.w3.org/2001/XMLSchema#string

U Verma

http://www.w3.org/2001/XMLSchema#string

Y Arriaga

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Diabetic nephropathy: diagnosis, prevention, and treatment.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

P304

960-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS593

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233750989

http://www.w3.org/2001/XMLSchema#string

P698

23175623

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.

about

P2860

P2860

Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921